Kisspeptin is a neuropeptide best understood as the signal at the top of the hypothalamic-pituitary-gonadal (HPG) axis — upstream even of gonadotropin-releasing hormone (GnRH). Peptide Data grades it Moderate, and that grade reflects a specific shape of evidence: a coherent and mechanistically clean set of Phase 1 and Phase 2 human studies, almost all from one research group, with no Phase 3 programme behind them. This piece sets out what kisspeptin is, what the human literature measured, where it thins out, and how UK law treats it.
01 — What kisspeptin is
Kisspeptin is the product of the KISS1 gene. It was first identified as a metastasis-suppressor gene and only later recognised as central to reproductive biology, when loss-of-function mutations in its receptor were linked to absent puberty (Seminara et al., 2003). The gene product is cleaved into several bioactive fragments. Kisspeptin-54 — also called metastin — is the longest and is the form most often used in human studies; kisspeptin-10 is the shortest commonly studied fragment, with kisspeptin-13 and kisspeptin-14 also occurring. The peptide has a short circulating half-life, on the order of a few minutes after intravenous administration and longer after subcutaneous administration, which is one reason the human studies have been acute rather than chronic.
02 — The mechanism
Kisspeptin binds the KISS1R receptor (historically known as GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release into the hypothalamic-pituitary portal system. GnRH then drives anterior-pituitary secretion of luteinising hormone (LH) and follicle-stimulating hormone (FSH), which in turn act on the gonads to produce sex steroids — testosterone and oestradiol — and gametes. Because kisspeptin acts upstream of GnRH rather than directly on the pituitary, it is one of the most potent known physiological stimuli of reproductive-hormone secretion, and it is a node through which metabolic and other cues are integrated into that axis.
03 — What the human evidence shows
The human dataset is small but unusually coherent. Dhillo et al. (2005) showed that kisspeptin-54 stimulated the HPG axis in healthy men, raising LH and testosterone. Jayasena et al. (2013, 2014) demonstrated that subcutaneous kisspeptin-54 increased LH pulsatility in women with hypothalamic amenorrhoea, and a 2014 study in the Journal of Clinical Investigation showed that kisspeptin-54 could trigger egg maturation in women undergoing in vitro fertilisation. George et al. (2015) found kisspeptin-10 to be a potent stimulator of LH in men, increasing pulse frequency.
Taken together, these studies establish a consistent, dose-dependent effect on LH, FSH and downstream sex steroids across both sexes and in both healthy and hypogonadal states. That consistency is why the compound sits at Moderate rather than Limited.
04 — Where the evidence is thin
Three limits matter for anyone reading this literature.
First, concentration. The published human work comes predominantly from a single research group at Imperial College London. Replication by independent groups is thin, which matters because effect sizes and safety observations from one centre carry less weight than the same findings reproduced across several.
Second, the studies are acute. They administer kisspeptin over short windows and measure hormonal responses. There is no established chronic protocol in the literature, and no long-term human safety or tolerability dataset of the kind a chronic-use question would require.
Third, the endpoints are hormonal or reproductive surrogates — LH, FSH, testosterone, oestradiol, egg maturation — not clinical outcomes. No Phase 3 trial has been completed, so there is no pivotal evidence that would support a licensed indication.
05 — The UK regulatory position
Kisspeptin is legal to purchase and possess for research purposes in the United Kingdom. It is not a licensed medicine, is not MHRA-licensed for any therapeutic indication, and is not scheduled under the Misuse of Drugs Act 1971. The human studies cited here were conducted under clinical trial authorisations, within the framework of the Medicines Act 1968 and the Human Medicines Regulations 2012.
Any product offered to UK buyers as kisspeptin for human use sits outside that licensed supply chain. As with all compounds on this site, the framing is research use only: this article describes published research findings and does not provide consumption, dosing or self-administration guidance.
06 — What the Moderate grade means
A Moderate grade is not a claim of clinical utility. It means the human evidence exists, is mechanistically plausible and points consistently in one direction, but is not yet at the depth — independent replication, chronic exposure data, clinical endpoints, a pivotal trial — that the Strong tier requires. Kisspeptin's grade is a statement about the state of the evidence, not a therapeutic endorsement, and it can move in either direction as independent groups publish.
Research use only. This compound is studied in preclinical and published research and is not licensed for human consumption in the UK.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.